Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07493538 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

StatusRecruiting

PhasePhase 2

SponsorMasonic Cancer Center, University of Minnesota

Started2026-04-10

View on ClinicalTrials.gov ↗

Amendment history

2026-04-13

Study Status, Contacts/Locations v2

Recruitment opened

Start dateestimated 2026-08→confirmed 2026-04-10

Study sites0→1

2026-03-30

Study Status, Arms and Interventions v1

Re-verified, no change to tracked fields

2026-03-20

Original filing

Masonic Cancer Center, University of Minnesota

58 trials monitored

See 2 trials at risk

2,553 trials monitored

See 134 trials at risk

Acute Myeloid Leukemia (AML)

1,196 trials monitored

See 63 trials at risk

Myelodysplastic Syndromes (MDS)

685 trials monitored

See 40 trials at risk

This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.

Trial Details

NCT Number	NCT07493538
Lead Sponsor	Masonic Cancer Center, University of Minnesota
Conditions	AML, MDS, Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Enrollment	132 participants
Start Date	2026-04-10
Primary Completion	2030-03 (estimated)
Study Completion	2035-03 (estimated)
Updated on ClinicalTrials.gov	2026-04-16